Results 171 to 180 of about 1,725,183 (344)
ABSTRACT Background Apolipoprotein ε4 (APOE ε4) is a potent genetic risk factor for Alzheimer's disease (AD). However, its role in cerebral small vessel disease (CSVD) remains unclear. Given the clinical and pathological similarities between CSVD and AD, this study aimed to investigate the associations of APOE ε4 gene dosage with cognitive function and
Tingru Jin +6 more
wiley +1 more source
Vasopressin-to-oxytocin receptor crosstalk in the preoptic area underlying parental behaviors in male mice. [PDF]
Inada K +6 more
europepmc +1 more source
Inhibition of sphingolipid synthesis affects axonal outgrowth in cultured hippocampal neurons
R. Harel, Anthony H. Futerman
openalex +1 more source
RAB39B Related Parkinsonism in an Italian Family: A Unique Use of Advanced Therapies
ABSTRACT Parkinson's disease (PD) is a neurodegenerative disorder that may sometimes be caused by deleterious genetic variants. Among them, RAB39B polymorphisms are known as rare causes of early‐onset PD associated with intellectual disability (Waisman's syndrome).
Caterina Del Regno +13 more
wiley +1 more source
EphB1-NR2B receptor signaling in glutamatergic neurons of the ventroposteromedial thalamic nucleus regulates emergence from anesthesia. [PDF]
Liu Y +6 more
europepmc +1 more source
Amyotrophic Lateral Sclerosis Prevalence Projection in 2040: A Less Rare Disease
ABSTRACT Objective To project ALS prevalence across multiple countries through 2040, accounting for both population aging and increased survival. Methods Data from the Piemonte and Valle d'Aosta ALS register (PARALS) was used to estimate the trends in incidence and prevalence from 2005 to 2019. Survival trends over this period were also assessed.
Rosario Vasta +18 more
wiley +1 more source
Anatomical and functional examination of superior colliculus projections to the inferior olivary in mice. [PDF]
David D, Nusselder H, Uusisaari MY.
europepmc +1 more source
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu +9 more
wiley +1 more source

